Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 16/20 | 0.50 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22422289 | 1.00 | PDE7A (0.50) | PDE7APDE7BCRBN | |
| SCHEMBL11491220 | 1.00 | PDE7A (0.50) | PDE7APDE7BCRBN | |
| SCHEMBL11870539 | 1.00 | PDE7A (0.50) | PDE7APDE7BCRBN | |
| SCHEMBL551553 | 1.00 | PDE7A (0.50) | PDE7APDE7BCRBN | |
| SCHEMBL542497 | 0.97 | PDE7A (0.47) | PDE7APDE7BCRBN | |
| SCHEMBL630549 | 0.92 | CRBN (0.43) | PDE7APDE7BCRBN | |
| SCHEMBL8775591 | 0.87 | — | — | |
| SCHEMBL23039345 | 0.86 | PDE7A (0.41) | PDE7APDE7BCRBN | |
| SCHEMBL4458582 | 0.81 | PDE7A (0.43) | PDE7APDE7B | |
| SCHEMBL31721361 | 0.81 | CRBN (0.40) | PDE7ACRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | claimed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | claimed |
| CN-111491930-B | Substituted Indole Compounds Useful as TLR Inhibitors | 百时美施贵宝公司 | 2023-09-26 | — | — | CN | claimed |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | claimed |
| EP-4090159-A1 | PYRAZOLYLPYRIMIDINES AND USE THEREOF | Biotheryx, Inc. (US) | 2022-11-23 | — | — | EP | claimed |
| US-20220331297-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2022-10-20 | — | — | US | claimed |
| WO-2021011868-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | claimed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | claimed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | claimed |
| EP-3710443-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | Arvinas Operations, Inc. (US) | 2020-09-23 | — | — | EP | claimed |
| US-20150191464-A1 | HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | claimed |
| US-8822516-B2 | Process for the preparation of iodides | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2014-09-02 | — | — | US | claimed |
| US-20130165658-A1 | PROCESS FOR THE PREPARATION OF IODIDES | TECHNION R&D FOUNDATION LTD. (IL) | 2013-06-27 | — | — | US | claimed |
| WO-2013001498-A1 | AMIDOALKYLPIPERAZINYL DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | ADAMED SP. Z O.O. (PL) | 2013-01-03 | — | — | WO | claimed |
| WO-2011154953-A1 | PROCESS FOR THE PREPARATION OF IODIDES | TECHNION R&D FOUNDATION LTD. (IL) | 2011-12-15 | — | — | WO | claimed |
| EP-1485057-B9 | DERIVATIVES OF AZASPIRO COMPOUNDS FOR THE TREATMENT OF PAIN | SANOL ARZNEI SCHWARZ GMBH (DE) | 2006-06-28 | — | — | EP | claimed |
| EP-1485057-B1 | DERIVATIVES OF AZASPIRO COMPOUNDS FOR THE TREATMENT OF PAIN | SANOL ARZNEI SCHWARZ GMBH (DE) | 2005-12-28 | — | — | EP | claimed |
| EP-0763073-A4 | — | — | 1997-04-16 | — | — | EP | claimed |
| EP-0763073-A1 | WET STRENGTH RESIN COMPOSITION AND METHODS OF MAKING THE SAME | HENKEL CORPORATION (US) | 1997-03-19 | — | — | EP | claimed |
| WO-1995027008-A1 | WET STRENGTH RESIN COMPOSITION AND METHODS OF MAKING THE SAME | HENKEL CORPORATION (US) | 1995-10-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PDE7A 1743/4885PDE7B 1473/4885CRBN 187/4885 |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PDE7A 1743/4885PDE7B 1473/4885CRBN 187/4885 |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PDE7A 1743/4885PDE7B 1473/4885CRBN 187/4885 |
| US-20220331297-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | PDE7A 1983/4885PDE7B 3854/4885CRBN 4/4885 |
| US-20130165658-A1 | PROCESS FOR THE PREPARATION OF IODIDES | NISCH, TPO, HDHD5 | PDE7A 1691/4885PDE7B 3219/4885CRBN 1229/4885 |
| US-20150191464-A1 | HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS | IRAK4, IRAK3, IRAK2 | PDE7A 971/4885PDE7B 1381/4885CRBN 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.